Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
dgTvMPX23WSVwS86
Listen
